Brief: Adaptive Biotech Announces Non-Dilutive Royalty Financing With Orbimed For Up To $250 Mln

Adaptive Biotechnologies

12/09/2022 13:41

Sept 12 (Reuters) - Adaptive Biotechnologies Corp  ADPT.O :
    * ADAPTIVE BIOTECHNOLOGIES ANNOUNCES NON-DILUTIVE ROYALTY
FINANCING WITH ORBIMED FOR UP TO $250 MILLION
    * ADAPTIVE - ORBIMED TO BE ENTITLED TO RECEIVE 5% OF CO'S
GAAP
REVENUES, INCREASING TO 8% & 10% IF SECOND & THIRD TRANCHES ARE
DRAWN, RESPECTIVELY

Source text for Eikon:  ID:nGNX5Nh5C5 
Further company coverage:  ADPT.O 

 ((Reuters.Briefs@thomsonreuters.com;))